How do statins interact with genes to upregulate the expression of PTB-1B in liver and adipose cells?
Best insight from top research papers
Statins upregulate the expression of PTB-1B in liver and adipose cells through various mechanisms. Lovastatin and simvastatin were found to increase the expression of Cytochrome P450 4F3B (CYP4F3B), which is involved in arachidonic acid metabolism and lipid metabolism . Pitavastatin and pravastatin were shown to induce the gene expression and synthesis of apolipoprotein A5 (apoA5), a key regulator of plasma triglyceride concentrations . Additionally, statins were found to upregulate small GTP-binding protein dissociation stimulator (SmgGDS) in endothelial cells through the β1-integrin/Akt1 pathway . The upregulation of SmgGDS by statins was associated with reduced oxidative stress and pleiotropic effects . However, there is no specific mention of statins interacting with genes to upregulate the expression of PTB-1B in liver and adipose cells in the provided abstracts.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
18 Citations | The provided paper does not mention the interaction of statins with genes to upregulate the expression of PTB-1B in liver and adipose cells. The paper focuses on the upregulation of SmgGDS in endothelial cells through the β1-integrin/Akt1 pathway. |
13 Citations | The provided paper does not mention the interaction of statins with genes to upregulate the expression of PTB-1B in liver and adipose cells. |
1 Citations | The provided paper does not mention the interaction of statins with the gene PTB-1B in liver and adipose cells. |
5 Citations | The provided paper does not mention the interaction of statins with genes to upregulate the expression of PTB-1B in liver and adipose cells. |
Open access 01 Dec 2011 1 Citations | The provided paper does not mention the interaction of statins with genes to upregulate the expression of PTB-1B in liver and adipose cells. |
Related Questions
Can statins cause issues with tendons?5 answersStatins have been associated with tendon issues. A cohort study found that regardless of the type of statin, their use was linked to a higher risk of developing various types of tendinopathy. Additionally, statin treatment has been shown to reduce the mechanical strength of tendon constructs, decrease collagen content, and alter gene expression related to tendon matrix quality. Furthermore, the co-administration of statins and gemfibrozil should raise awareness among prescribers regarding potential tendon-related complications, especially in high-risk populations with musculoskeletal comorbidities. These findings suggest that statins can indeed cause problems with tendons, highlighting the importance of monitoring and considering alternative treatments in patients at risk.
What is the relationship between statin use and the development of type 2 diabetes?5 answersStatin use has been associated with an increased risk of developing type 2 diabetes. Studies have shown that statin users, especially those on long-term and high-dose regimens, have a higher likelihood of new-onset type 2 diabetes compared to non-users. The risk of diabetes development with statin therapy has been observed across different patient populations, including those at high risk for diabetes. While some statins like pitavastatin and pravastatin may not significantly impact glycemic control, others like atorvastatin have shown a stronger diabetogenic effect. The evidence suggests that the relationship between statin use and type 2 diabetes risk is real, although the magnitude of this effect may vary among studies. Regular monitoring and screening for diabetes in long-term statin users are recommended to manage this potential risk.
Statins and diabetes: What are the connections?5 answersStatins have been associated with an increased risk of type 2 diabetes mellitus (T2DM). Randomized trials suggest that moderate- to high-intensity statins may increase the risk of T2DM by around 11% to 20% relative to placebo. Patients with diabetes who use statins have been found to have less control of their diabetes, higher chances of insulin treatment initiation, and increased risk of hyperglycemia and acute glycemic complications. Statins can increase the risk of newly diagnosed T2DM by 9%-12% and improve insulin resistance while inhibiting insulin secretion. The National Lipid Association (NLA) concluded that the cardiovascular benefits of statin therapy outweigh the risk of developing diabetes. In a high-risk population, statin therapy was associated with significantly higher rates of diabetes, suggesting that the effect of statins on increasing diabetes risk extends to populations at high risk for diabetes.
How do statins interact with the membrane channels of pancreatic cell? Explain the molecular mechanism?5 answersStatins, such as simvastatin and rosuvastatin, interact with the membrane channels of pancreatic cells by inhibiting voltage-gated potassium channels (Kv1.3 channels). The molecular mechanism of this interaction involves a direct interaction with the channel protein and perturbation of the lipid bilayer structure, leading to the stabilization of the inactivated state of the channels. Statins inhibit the mevalonate/cholesterol synthesis pathway, blocking the synthesis of intermediates important for prenylation and activation of the Ras/mitogen-activated protein kinase 1 signaling pathway. They also modulate the phosphoinositide 3-kinase/Akt serine/threonine kinase 1 and inflammation signaling pathways, and alter the expression of genes involved in lipid metabolism, which are important for pancreatic ductal adenocarcinoma growth and proliferation. The specific effects of statins on the membrane channels of pancreatic cells are still being investigated, but their potential as chemopreventive agents in pancreatic cancer is being explored.
What genes are associated with high blood cholesterol?5 answersMutations in genes such as LDLR, APOB, PCSK9, LDLRAP1, STAP1, CYP7A1, LIPA, ABCG5, ABCG8, and PNPLA5 have been associated with high blood cholesterol levels. Additionally, genome-wide association studies have identified over 200 genes involved in lipid metabolism that are associated with hypercholesterolemia and serum lipid traits. Some of these genes include NR1I2, STARD3, and FN1. Furthermore, a study identified missense mutations in APOE, LDLR, and PCSK9 that are strongly associated with high LDL cholesterol levels. Other candidate genes involved in cholesterol and triglyceride metabolism, such as the LDL receptor, are also implicated in high blood cholesterol and warrant further study.
What is the function of the Brsk1 gene in lipid metabolism?4 answersThe function of the BRG1 gene in lipid metabolism is to regulate lipid droplet deposition and alter the phosphoinositide-3-kinase adaptor protein 1 (PIK3AP1)/phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway in hepatocellular carcinoma (HCC) cells. BRG1 interacts with sterol response element binding protein (SREBP) to optimize chromatin structure and facilitate SREBP1c binding, thereby contributing to fatty acid esterification and hepatic lipid metabolism. BRG1 deficiency leads to reduced processing and nuclear accumulation of SREBP, resulting in impaired lipid metabolism in non-alcoholic steatohepatitis (NASH). Overall, BRG1 plays an essential role in regulating lipid metabolism by modulating the expression of key genes involved in lipid synthesis and storage.